NOTICE: April 2018 was the final issue of this publication.

We will continue providing valuable clinical and pharmacological updates in Internal Medicine Alert and Primary Care Reports. Read More

Comparing GLP-1 Agonists

There are more similarities than differences among the seven currently available glucagon-like peptide-1 (GLP-1) receptor agonists. The most recently FDA-approved GLP-1 receptor agonist, once-weekly semaglutide (Ozempic), was compared in a head-to-head trial to once-weekly exenatide-ER (Bydureon).

Rivaroxaban vs. Aspirin for Prevention of VTE

Might direct oral coagulants offer some advantage for extended venous thromboembolism (VTE) thromboprophylaxis in patients undergoing knee or hip arthroplasty who are known to suffer an increased risk of VTE in the immediate postoperative period?

Inhaled Corticosteroids and Fracture Risk

Clinicians should strive to use the minimum inhaled corticosteroids necessary to achieve symptomatic improvements in COPD patients.

Obstructive Sleep Apnea: Oral Appliances

The diversity of treatment options currently available should stimulate optimism that the consequences of obstructive sleep apnea can be improved successfully in most patients.

Influenza Increases Rate of Myocardial Infarction

The proportion of patients who succumb to influenza pneumonia vs. those who incur bacterial pneumonia subsequent to pneumonia vs. all other incident pneumonias that occur concomitantly with flu season is not readily discernible.